Tumor necrosis factor receptors: Biology and therapeutic potential in kidney diseases

American Journal of Nephrology

Volumn 36, Issue 3, 2012, Pages 261-270

  Speeckaert, Marijn M ^a,b   Speeckaert, Reinhart ^b   Laute, Margo ^a   Vanholder, Raymond ^a   Delanghe, Joris R ^b  

^a Department of Nephrology ^*  (Turkey)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Renal pathology; Tumor necrosis factor receptor; Tumor necrosis factor

Indexed keywords

ALBUMIN; BIOTIN; ENDOTOXIN; HORSERADISH PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; STREPTAVIDIN; TETRAMETHYLBENZIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN RECEPTOR 2;

ACUTE GRAFT REJECTION; ANTIBODY LABELING; ASTHMA; AUTOIMMUNE DISEASE; CALIBRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEX FORMATION; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HEART MUSCLE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFLAMMATION; INOTROPISM; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RENOVASCULAR DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTOLIC BLOOD PRESSURE; TRANSACTIVATION; URINARY TRACT OBSTRUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; INFLAMMATION; KIDNEY DISEASES; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MICE; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEPSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865843591     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000342333     Document Type: Review

References (80)

1. Lorenzen I, Trad A, Grötzinger J: Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM-17) is mediated by its EGF-like domain. Biochem Biophys Res Commun 2011; 415: 330-336.
2. Richter C, Messerschmidt S, Holeiter G, et al: The TNF receptor stalk regions define responsiveness to soluble versus membrane bound ligand. Mol Cell Biol 2012; 32: 2515-2529.
3. Cabal-Hierro L, Lazo PS: Signal transduction by tumor necrosis factor receptors. Cell Signal 2012; 24: 1297-1305.
4. Inukai T, Uchida K, Nakajima H, et al: Tumor necrosis factor- and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twy/twy) sustaining chronic mechanical compression. Spine (Phila Pa 1976) 2009; 34: 2448-2457.
5. Yan M, Xia C, Cheng C, et al: The role of TNF- and its receptors in the production of Src-suppressed C kinase substrate by rat primary type-2 astrocytes. Brain Res 2007; 1184: 28-37.
6. Chen X, Oppenheim JJ: Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 2011; 585: 3611-3618.
7. Defer N, Azroyan A, Pecker F, Pavoine C: TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem 2007; 282: 35564-35573.
8. Grell M, Becke FM, Wajant H, Männel DN, Scheurich P: TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 1998; 28: 257-263.
9. Ding B, Kirkiles-Smith NC, Pober JS: FOXO3a regulates oxygen-responsive expression of tumor necrosis factor receptor 2 in human dermal microvascular endothelial cells. J Biol Chem 2009; 284: 19331-19339.
10. Kelly ML, Wang M, Crisostomo PR, et al: TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock 2010; 33: 602-607.
11. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR: Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81: 1503-1515.
12. Baud L, Ardaillou R: Tumor necrosis factor in renal injury. Miner Electrolyte Metab 1995; 21: 336-341.
13. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
14. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF: Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics 1992; 13: 219-224.
15. Beltinger CP, White PS, Maris JM, et al: Physical mapping and genomic structure of the human TNFR2 gene. Genomics 1996; 35: 94-100.
16. Nishimura M, Obayashi H, Mizuta I, et al: TNF, TNF receptor type 1, and allograft inflammatory factor-1 gene polymorphisms in Japanese patients with type 1 diabetes. Hum Immunol 2003; 64: 302-309.
17. Gordon AC, Lagan AL, Aganna E, et al: TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004; 5: 631-640.
18. Rangan G, Wang Y, Harris D: NF- B signalling in chronic kidney disease. Front Biosci 2009; 14: 3496-3522.
19. Fujita K, Srinivasula SM: Ubiquitination and TNFR1 signaling. Results Probl Cell Differ 2009; 49: 87-114.
20. Zhu LJ, Yang X, Li XY, et al: Suppression of tumor necrosis factor receptor associated factor-2 attenuates the proinflammatory and proliferative effect of aggregated IgG on rat renal mesangial cells. Cytokine 2010; 49: 201-208.
21. Vielhauer V, Stavrakis G, Mayadas TN: Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005; 115: 1199-1209.
22. Tartaglia LA, Pennica D, Goeddel DV: Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
23. Ernandez T, Mayadas TN: Immunoregulatory role of TNF- in inflammatory kidney diseases. Kidney Int 2009; 76: 262-276.
24. Hawari FI, Rouhani FN, Cui X, et al: Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci USA 2004; 101: 1297-1302.
25. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
26. Lantz M, Malik S, Slevin ML, Olsson I: Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990; 2: 402-406.
27. Gohda T, Niewczas MA, Ficociello LH, et al: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524.
28. Niewczas MA, Gohda T, Skupien J, et al: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515.
29. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S: Urinary excretion of soluble tumour necrosis factor receptor-1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant 2010; 25: 3948-3956.
30. Porteu F, Nathan C: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599-607.
31. Waetzig GH, Rosenstiel P, Arlt A, et al: Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-1 . FASEB J 2005; 19: 91-93.
32. Bouma MG, Buurman WA: Assay of soluble tumor necrosis factor receptors. Methods Mol Med 2000; 36: 91-100.
33. Niewczas MA, Ficociello LH, Johnson AC, et al: Serum concentrations of markers of TNF- and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4: 62-70.
34. Rauert H, Stühmer T, Bargou R, Wajant H, Siegmund D: TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2011; 2:e194.
35. Al-Lamki RS, Wang J, Vandenabeele P, et al: TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645.
36. Bachmeier BE, Nerlich AG, Weiler C, Paesold G, Jochum M, Boos N: Analysis of tissue distribution of TNF- , TNF- receptors, and the activating TNF-converting enzyme suggests activation of the TNF- system in the aging intervertebral disc. Ann NY Acad Sci 2007; 1096: 44-54.
37. Al-Lamki RS, Sadler TJ, Wang J, et al: Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 2010; 177: 943-954.
38. Castillo A, Islam MT, Prieto MC, Majid DS: Tumor necrosis factor- receptor type 1, not the type 2, mediates its acute responses in the kidney. Am J Physiol Renal Physiol 2012; 302:F1650-1657.
39. Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten BI, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11: 1426-1438.
40. Gaeta ML, Johnson DR, Kluger MS, Pober JS: The death domain of tumor necrosis factor receptor 1 is necessary but not sufficient for Golgi retention of the receptor and mediates receptor desensitization. Lab Invest 2000; 80: 1185-1194.
41. Wittebole X, Coyle SM, Kumar A, Goshima M, Lowry SF, Calvano SE: Expression of tumour necrosis factor receptor and Toll-like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of flow cytometric light scatter and immunofluorescence gating. Clin Exp Immunol 2005; 141: 99-106.
42. Takasugi K, Yamamura M, Iwahashi M, et al: Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R126.
43. Zola H, Flego L, Weedon H: Expression of membrane receptor for tumour necrosis factor on human blood lymphocytes. Immunol Cell Biol 1993; 71: 281-288.
44. Chan FK, Siegel RM, Zacharias D, et al: Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signaling using spectral variants of the green fluorescent protein. Cytometry 2001; 44: 361-368.
45. Blackwell K, Zhang L, Thomas GS, Sun S, Nakano H, Habelhah H: TRAF2 phosphorylation modulates tumor necrosis factor-induced gene expression and cell resistance to apoptosis. Mol Cell Biol 2009; 29: 303-314.
46. Zhou M, Zhang Y, Ardans JA, Wahl LM: Interferon- differentially regulates monocyte matrix metalloproteinase-1 and-9 through tumor necrosis factor- and caspase-8. J Biol Chem 2003; 278: 45406-45413.
47. Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
48. Hasegawa G, Nakano K, Sawada M, et al: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012.
49. Miyazawa I, Araki S, Obata T, et al: Association between serum soluble TNF- receptors and renal dysfunction in type 2 diabetic patients without proteinuria. Diabetes Res Clin Pract 2011; 92: 174-180.
50. Safranow K, Dziedziejko V, Rzeuski R, et al: Plasma concentrations of TNF- and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 2009; 74: 386-392.
51. Kowalska I, Straczkowski M, Nikolajuk A, et al: Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism 2008; 57: 1539-1544.
52. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR: Elevated soluble tumor necrosis factor receptor levels in nonobese adults with the atherogenic dyslipoproteinemia. Atherosclerosis 2004; 177: 77-81.
53. Chen CC, Pedraza PL, Hao S, Stier CT, Ferreri NR: TNFR1-deficient mice display altered blood pressure and renal responses to ANG-II infusion. Am J Physiol Renal Physiol 2010; 299:F1141-F1150.
54. Defer N, Azroyan A, Pecker F, Pavoine C: TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem 2007; 282: 35564-35573.
55. Reinhold SW, Straub RH, Krüger B, et al: Elevated urinary sVCAM-1, IL-6, sIL-6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first two weeks after transplantation. Cytokine 2012; 57: 379-388.
56. Wang J, Li Z, Al-Lamki R, et al: The role of tumor necrosis factor- converting enzyme in renal transplant rejection. Am J Nephrol 2010; 32: 362-368.
57. Hoffmann U, Bergler T, Rihm M, et al: Upregulation of TNF receptor type 2 in human and experimental renal allograft rejection. Am J Transplant 2009; 9: 675-686.
58. Qi H, Ohh M: The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor- B-dependent antiapoptotic pathway. Cancer Res 2003; 63: 7076-7080.
59. Rosenkranz AR, Knight S, Sethi S, Alexander SI, Cotran RS, Mayadas TN: Regulatory interactions of-and-T cells in glomerulonephritis. Kidney Int 2000; 58: 1055-1066.
60. Hasegawa M, Nishii C, Ohashi A, et al: Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Nephron Clin Pract 2009; 113:c222-233.
61. Wu T, Xie C, Wang HW, et al: Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179: 7166-7175.
62. Zhu L, Yang X, Ji Y, et al: Up-regulated renal expression of TNF- signalling adapter proteins in lupus glomerulonephritis. Lupus 2009; 18: 116-127.
63. Bruggeman LA, Drawz PE, Kahoud N, Lin K, Barisoni L, Nelson PJ: TNFR2 interposes the proliferative and NF- B-mediated inflammatory response by podocytes to TNF- . Lab Invest 2011; 91: 413-425.
64. Merkle M, Ribeiro A, Wörnle M: TLR3-dependent regulation of cytokines in human mesangial cells: a novel role for IP-10 and TNF- in hepatitis C-associated glomerulonephritis. Am J Physiol Renal Physiol 2011; 301:F57-F69.
65. Spies M, Chappell VL, Dasu MR, Herndon DN, Thompson JC, Wolf SE: Role of TNF- in gut mucosal changes after severe burn. Am J Physiol Gastrointest Liver Physiol 2002; 283:G703-G708.
66. Fang WH, Yao YM, Shi ZG, et al: The mRNA expression patterns of tumor necrosis factor- and TNFR-I in some vital organs after thermal injury. World J Gastroenterol 2003; 283:G703-G708.
67. Pfeffer K, Matsuyama T, Kündig TM, et al: Mice deficient for the 55-kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-467.
68. Misaki T, Yamamoto T, Suzuki S, et al: Decrease in tumor necrosis factor- receptorassociated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats. Am J Pathol 2009; 175: 74-83.
69. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S: Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277:F766-F772.
70. Choi YJ, Baranowska-Daca E, Nguyen V, et al: Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules. Kidney Int 2000; 58: 1481-1491.
71. Misseri R, Meldrum DR, Dinarello CA, et al: TNF- mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005; 288:F406-F411.
72. Meldrum KK, Metcalfe P, Leslie JA, Misseri R, Hile KL, Meldrum DR: TNF- neutralization decreases nuclear factor- B activation and apoptosis during renal obstruction. J Surg Res 2006; 131: 182-188.
73. Meldrum KK, Misseri R, Metcalfe P, Dinarello CA, Hile KL, Meldrum DR: TNF- neutralization ameliorates obstruction-induced renal fibrosis. Am J Physiol Regul Integr Comp Physiol 2007; 292: 1456-1464.
74. Van Hauwermeiren F, Vandenbroucke RE, Libert C: Treatment of TNF-mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 2011; 22: 311-319.
75. Faustman D, Davis M: TNF receptor-2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010; 9: 482-493.
76. Aringer M, Smolen JS: The role of tumor necrosis factor- in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.
77. Wang GB, Li CR, Yang J, Wen PQ, Jia SL: A regulatory polymorphism in promoter region of TNFR1 gene is associated with Kawasaki disease in Chinese individuals. Hum Immunol 2011; 72: 451-457.
78. Keystone EC, Ware CF: Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl 2010; 85: 27-39.
79. Fotin-Mleczek M, Henkler F, Samel D, et al: Apoptotic crosstalk of TNF receptors: TNFR2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 2002; 115: 2757-2770.
80. Rodríguez M, Cabal-Hierro L, Carcedo MT, et al: NF- B signal triggering and termination by tumor necrosis factor receptor-2. J Biol Chem 2011; 286: 22814-22824.